18449431_1540572369300682_5569695805343340954_o.jpg

Investment Opportunity:

Altopa is currently raising $3M to close our $5M Preferred Series A round. We will use these funds to complete a final round of engineering and testing, including an external beta launch, and transfer our inventory build process to contract manufacturing.  Additionally, we will use these funds to conduct a pilot commercial launch in late 2018 and target high-usage medicinal cannabis consumers in Oregon and Washington.

Management plans to raise our last round of financing in early 2019 to support inventory build and national commercialization. Given that we will be generating revenue, we anticipate that this last round of financing will be sourced through an institutional lender or a royalty fund. Based on our projections, we expect to be cash flow positive within 18 months of our commercial launch.

The Series A round represents Altopa’s second round of financing. In 2016, Altopa closed a $1.4M Preferred Series Seed equity round. This financing enabled the company to build Altopa’s executive team, develop a beta-ready Oblend, create the Oblend app, file 26 patent applications (1 patent has been granted), develop supply chain and sales channels, and perform extensive market research.

Altopa, The Ideal Investment

  • Multiple Sources of Recurring Revenue with High Margins

  • Decades of Experience in Healthcare, Technology, Health & Wellness

  • Targeting Fastest Growing Industry with Disruptive Product

  • Oblend App Collecting User Data (Long-Term Value)

  • “Hands-Off” Operating Model (we don’t touch the plant)

  • Cash Flow Positive 18 Months Post Commercial Launch

  • Multiple Platform Expansion and Exit Opportunities

Traction Achieved

  • CES 2018 Innovation Award Winner

  • Selected as 1 of 9 Companies Featured on National TV Series

  • Oblend Device & App Ready for Beta Testing

  • 26 Patent Applications Filed; 1 Patent Issued

  • Initial Supply Chain and Sales Channels Identified

  • Key Strategic Partnerships Formed

Contact us to learn about the investment opportunity


Put me on the Pre-Sale list